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he recent development of neuroimaging tech-
nologies that permit in vivo characterization of the
anatomical,physiological,and receptor pharmacological
correlates of mood disorders have enabled significant
advances toward delineating the neurobiological corre-
lates of mood disorders.Because these conditions were
not associated with gross brain pathology or with clear
animal models for spontaneous,recurrent mood episodes,
the availability of tools allowing noninvasive assessment
of the human brain proved critical to illuminating the
pathophysiology of major depressive disorder (MDD)
and bipolar disorder (BD).The results of studies apply-
ing imaging technologies and postmortem studies have
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Neuroimaging and neuropathological studies of major depressive disorder (MDD) and bipolar disorder (BD) have iden-
tified abnormalities of brain structure in areas of the prefrontal cortex, amygdala, striatum, hippocampus, parahip-
pocampal gyrus, and raphe nucleus. These structural imaging abnormalities persist across illness episodes, and prelimi-
nary evidence suggests they may in some cases arise prior to the onset of depressive episodes in subjects at high familial
risk for MDD. In other cases, the magnitude of abnormality is reportedly correlated with time spent depressed.
Postmortem histopathological studies of these regions have shown abnormal reductions of synaptic markers and glial
cells, and, in rare cases, reductions in neurons in MDD and BD. Many of the regions affected by these structural abnor-
malities show increased glucose metabolism during depressive episodes. Because the glucose metabolic signal is domi-
nated by glutamatergic transmission, these data support other evidence that excitatory amino acid transmission is ele-
vated in limbic-cortical-striatal-pallidal-thalamic circuits during depression. Some of the subject samples in which these
metabolic abnormalities have been demonstrated were also shown to manifest abnormally elevated stressed plasma cor-
tisol levels. The co-occurrence of increased glutamatergic transmission and cortisol hypersecretion raises the possibility
that the gray matter volumetric reductions in these depressed subjects are partly accounted for by processes homologous
to the dendritic atrophy induced by chronic stress in adult rodents, which depends upon interactions between elevated
glucocorticoid secretion and N-methyl-D-aspartate (NMDA)–glutamate receptor stimulation. Some mood-stabilizing and
antidepressant drugs that exert neurotrophic effects in rodents appear to reverse or attenuate the gray matter volume
abnormalities in humans with mood disorders. These neurotrophic effects may be integrally related to the therapeutic
effects of such agents, because the regions affected by structural abnormalities in mood disorders are known to play
major roles in modulating the endocrine, autonomic, behavioral, and emotional experiential responses to stressors.  
© 2004, LLS SAS Dialogues Clin Neurosci. 2004;6:199-216.guided clinical neuroscience toward models in which
both functional and structural brain pathology play roles
in the pathogenesis of mood disorders.
Longitudinal positron emission tomography (PET) imag-
ing studies of MDD and BD identified abnormalities of
regional cerebral glucose metabolism and cerebral blood
flow (CBF),which,in some cases,persisted beyond symp-
tom remission,and in other cases appeared mood state-
dependent (reviewed in reference 1; Figure 1). These
reversible abnormalities presumably reflect areas where
metabolic activity increases or decreases to mediate or
respond to emotional and cognitive manifestations of the
depressive syndrome,because local glucose metabolism
and CBF (which is tightly coupled to glucose metabo-
lism) reflect summations of the energy utilization associ-
ated with terminal field synaptic transmission during
neural activity.
2-4 In contrast,abnormalities that persist
independently of the mood state may instead reflect neu-
ropathological sequelae of recurrent illness or neurode-
velopmental abnormalities that may confer vulnerability
to MDD (eg,in cases where they are evident in otherwise
healthy individuals at high familial risk for developing
mood disorders).Such abnormalities in CBF and metab-
olism may reflect pathological changes in synaptic trans-
mission associated with altered neurotransmitter recep-
tor function,cerebrovascular disease,changes in neuronal
arborization or synapse formation,or abnormalities in
cellular viability or proliferation.
5 For example, areas
where CBF and metabolism appeared irreversibly
decreased in depressives relative to controls in PET stud-
ies of MDD and BD were subsequently associated with
focal tissue reductions in magnetic resonance imaging
(MRI)–based morphometric and postmortem histopatho-
logical studies of MDD and BD.
6-10
Abnormalities of gray matter volume and histology have
now been identified in several brain structures using vol-
umetric MRI and postmortem neuropathological assess-
ments,which in many cases were guided by initial appli-
cation of functional imaging approaches. The regions
affected by these abnormalities have been shown to play
major roles in modulating emotional behavior by elec-
trophysiological,lesion analysis,and functional neuro-
imaging studies in experimental animals and healthy
humans. Thus, the structural abnormalities in these
regions may prove relevant to the emotional dysregula-
tion that is clinically manifest in mood disorders.
Sensitivity for detecting neuroimaging 
abnormalities in depression
The neuroimaging abnormalities discovered to date have
not had effect sizes sufficient to permit sensitive or spe-
cific classification of individual cases.Moreover,the psy-
chiatric imaging literature is in disagreement regarding
the specific location and direction of some abnormalities.
Many limitations in the sensitivity in reproducing find-
ings across studies appear to be accounted for simply by
technical issues of image acquisition and/or analysis.
1 In
other cases,however,disagreements within the literature
appear to reflect differences in subject selection criteria
applied across studies, because the conditions encom-
passed by the diagnostic criteria for MDD appear to be
heterogeneous with respect to pathophysiology and eti-
ology.
It is noteworthy that neuroimaging laboratories selecting
depressed subjects according to MDD criteria alone have
rarely been able to replicate their own previous findings
in independent subject samples.Instead,neuroimaging
abnormalities appear to be specific to subsets of MDD
subjects.
1 For example,requiring that subjects have famil-
ial aggregation of illness and an early age at illness onset
improved sensitivity for identifying subject samples with
reproducible neuroimaging abnormalities.Clinical dif-
ferences related to the capacity for developing mania or
psychosis or having a late age at illness onset have also
been shown to influence neuroimaging data.For exam-
ple,elderly MDD subjects with a late age at depression
onset have an elevated prevalence of MRI signal hyper-
intensities (in T2-weighted MRI scans,as putative corre-
lates of cerebrovascular disease) in the deep and periven-
tricular white matter, which is not the case for elderly
depressives with an early age at depression onset.
Similarly,elderly MDD cases with a late-life onset and
delusional MDD cases have been shown to have lateral
ventricular enlargement—a feature which is generally
not present in MDD cases who are elderly but have an
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Selected abbreviations and acronyms
ACC anterior cingulate cortex
BD bipolar disorder
FPDD familial pure depressive disease
5-HT 5-hydroxytryptamine (serotonin)
MDD major depressive disorder
NMDA  N-methyl-D-aspartate
PFC prefrontal cortex
VTA ventral tegmental areaearly age of MDD onset,or in midlife depressives who
are not delusional.In addition,enlargement of the third
ventricle has been consistently reported in BD,but not
in MDD.
A major technical issue that influences the sensitivity for
detecting neuroimaging abnormalities across studies is
the low spatial resolution of imaging technology relative
to the size of brain structures of primary interest.With
respect to morphometric assessments of gray matter vol-
ume,the volumetric resolution of state-of-the-art image
data has recently been about 1 mm
3,compared with the
cortex thickness of only 3 to 4 mm.MRI studies involv-
ing images of this resolution have been able to repro-
ducibly show regionally specific reductions in mean gray
matter volume across groups of clinically similar depres-
sives versus controls.However,they have lacked sensi-
tivity to detect the relatively subtle tissue reductions
extant in mood disorders in individual subjects.
Moreover,studies attempting to replicate such findings
using data acquired at lower spatial resolutions (ie,voxel
sizes ≥1.5 mm
3) have commonly been negative because
of the substantial partial volume effects that arise when
attempting to segment regions of only 3- to 4-mm cortex
thickness in such low-resolution MRI images.
Volumetric MRI imaging abnormalities in
mood disorders
Frontal lobe structures
Volumes of the whole brain and entire frontal lobe gen-
erally have not differed between depressed and healthy
control samples. In contrast, volumetric abnormalities
have been identified in specific prefrontal cortical (PFC),
mesiotemporal,and basal ganglia structures in mood dis-
orders.The most prominent reductions in the cortex have
been identified in the anterior cingulate gyrus ventral to
the genu of the corpus callosum,where gray matter vol-
ume has been abnormally decreased 20% to 40% in
depressed subjects with familial pure depressive disease
(FPDD),familial BD,and psychotic depression
6,11-13 rela-
tive to healthy controls or mood-disordered subjects with
no first-degree relatives with mood disorders.These find-
ings were confirmed by postmortem studies of clinically
similar samples (see below). Effective treatment with
selective serotonin (5-hydroxytryptamine [5-HT]) reup-
take inhibitors did not alter the subgenual PFC volume
in MDD,
6 although the PFC appeared significantly larger
in BD subjects chronically medicated with lithium or
divalproex than BD subjects who were either unmed-
icated or medicated with other agents,
1 compatible with
evidence that chronic administration of these mood sta-
bilizers increases expression of the neurotrophic factors
in rodents.
14
In the posterior orbital,cortex,and ventrolateral PFC,
volume has also been shown to be reduced in in vivo vol-
umetric MRI studies
15,16 and in postmortem neuropatho-
logical studies of MDD.
17,18 Reductions in gray matter 
volume were also found in the dorsomedial/dorsal
anterolateral PFC in MDD subjects versus controls,
19 and
postmortem studies of MDD and BD reported abnormal
reductions in the size of neurons and/or the density of
glia.
18,20,21
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Figure 1. Summary of neuroimaging abnormalities in early-onset, pri-
mary, major depressive disorder (MDD). The regions where
neurophysiological imaging abnormalities have been consis-
tently reported in unmedicated MDD samples are listed and
approximately shown on this midsagittal brain diagram in
which subcortical structures are highlighted onto the medial
surface. Because only the medial wall of the cortex is shown,
the location of the lateral orbital/ventrolateral prefrontal cor-
tex (PFC)/anterior insular region is better illustrated in Figure
2B. The “ventral anterior cingulate” region refers to both pre-
genual and subgenual portions (see text and Figure 2). The
arrows in front of each region name indicate the direction of
resting state abnormalities in glucose metabolism in unmed-
icated, depressed MDD samples relative to healthy control sam-
ples. In some cases, abnormalities in both directions have been
reported which may depend either on the specific region
involved or on the clinical state (eg, treatment responsive vs
nonresponsive; see text). The red arrows have indicate
histopathological and/or gray matter volumetric abnormalities
in postmortem studies of primary mood disorders. 
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Morphometric MRI studies of specific temporal lobe
structures reported significant reductions in the hip-
pocampal volume in MDD, with magnitudes of differ-
ence ranging from 8% to 19% with respect to healthy
controls.
22-28 Sheline et al
23 and MacQueen et al
28 reported
that the hippocampal volume was negatively correlated
with the total time spent depressed or with the number
of depressive episodes in MDD.Other groups found no
significant differences between MDD and control sam-
ples.
29-35The inconsistency in the results of MDD studies
may reflect pathophysiological heterogeneity within the
MDD samples studied.For example,Vythilingam et al
36
reported that the hippocampal volume was abnormally
decreased in depressed women who also had suffered
early-life trauma,but not in women who had depression
without early-life trauma.
In BD,reductions in hippocampal volume were identi-
fied by Noga et al
37 and Swayze et al
38 relative to healthy
controls, although Pearlson et al
39 and Nugent et al
27
found no differences between BD and control samples.
In postmortem studies of BD,abnormal reductions in the
mRNA concentrations of synaptic proteins
40 and in api-
cal dendritic spines of pyramidal cells
41 were specifically
observed in the subicular and ventral CA1 subregions of
the hippocampus.A recent study using high-resolution
MRI scans found that the volume of the subiculum,but
not the remainder of the hippocampus,was decreased in
BD relative to control samples.
27
Two studies reported abnormalities of the hippocampal
T1 MRI signal in MDD.Krishnan et al
42 observed that the
T1 relaxation time was reduced in the hippocampus,but
not in the entire temporal lobe,in unipolar depressives
relative to healthy controls,and Sheline et al
23 observed
that elderly subjects with MDD have a higher number of
areas with a low MRI signal than age-matched controls
in T1-weighted images.The significance of such abnor-
malities remains unclear.
In the amygdala,the literature is in disagreement.Studies
of MDD have reported that amygdala volume is
decreased,
43,44 increased,
45 or not different
26 in depressives
relative to healthy controls.Similarly,in BD,amygdala
volume was reported to be increased,
46-48 decreased,
39,49,50
or not different
38 relative to healthy controls.Although
the extent to which disagreements in the results across
studies are accounted for by confounding factors (such
as medication effects) remains unclear,it appears more
likely that MRI images acquired at ≤1.5 tesla lack the
spatial and tissue contrast resolution needed to measure
amygdala volumes with sufficient validity and reliability.
The amygdala’s small size and proximity to other gray
matter structures seriously limits the specificity (accu-
racy) for delimiting amygdala boundaries in images
acquired using MRI scanners of ≤1.5-tesla field strength.
High-resolution MRI images acquired at 3-tesla mag-
netic field strength,in contrast,permit valid and reliable
volumetric measures of the human amygdala.A recent
study employing this technique established that mean
amygdala volumes are decreased bilaterally (P<0.001) in
MDD relative to healthy control samples.
51 Amygdala
volumes were decreased both in currently depressed and
currently remitted MDD subsamples.Although mean
amygdala volumes did not differ between BD and con-
trol samples,they were smaller in BD subjects who had
not been recently medicated with mood stabilizers than
in BD subjects who had been taking such agents,consis-
tent with evidence that some mood stabilizers exert neu-
rotrophic effects.
14
Basal ganglia
Volumes of some basal ganglia structures have also been
reported to be abnormally decreased in mood disorders.
Husain et al
52 reported that the putamen was smaller in
depressives (mean age 55) than controls,and Krishnan et
al
53 found a smaller caudate nucleus volume in depressives
(mean age 48) than controls.In a sample limited to elderly
depressives,Krishnan et al
54 also reported smaller putamen
and caudate volumes relative to controls.These findings
were consistent with the postmortem study of Baumann
et al,
55 which found that caudate and accumbens area vol-
umes were markedly decreased in both MDD and BD
samples relative to control samples.Nevertheless,Dupont
et al
56 and Lenze et al
57 failed to find significant differences
in caudate or lentiform nucleus (putamen plus globus pal-
lidus) volumes between younger MDD subjects and con-
trols. The factors accounting for the discrepant results
across studies remain unclear.
Abnormalities of corpus callosal volume in mood 
disorders
The genual subsection of the corpus callosum was
reduced in volume in both depressed women with MDD
and their high-risk,female offspring (insufficient num-
Clinical research
202bers of males were studied to determine whether the
abnormality extends to males).
58,59 These white matter
regions contain the transcallosal fibers connecting the
orbital cortex, anterior cingulate cortex (ACC), and
medial PFC with their homologous cortices in the con-
tralateral hemisphere.The volumes of the splenial sub-
region of the corpus callosum was also decreased in
mood-disordered versus control samples,which contains
transcallosal fibers from the posterior cingulate cortex.
Other cerebral structures
Morphometric studies of other brain structures in
depression have produced less consistent results.Of MRI
studies of the thalamus,Dupont et al
56 reported that the
thalamic volume was decreased in unipolar depressives
relative to controls,but Krishnan et al
42,54 found no dif-
ferences between depressives and controls.Two studies
of thalamic volume in BD also have reported conflicting
results.Of MRI studies of the cerebellum,two reported
that the vermal volume is reduced in depressives relative
to controls,
60,61 while a third did not.
62
Consistent with evidence that the hypothalamic-pitu-
itary-adrenal (HPA) axis function is elevated in some
mood-disordered subgroups,enlargement of the pituitary
and adrenal glands has been reported in MDD.Krishnan
et al
63 showed that MRI-based measures of cross-sec-
tional area and volume of the pituitary were increased
(by 34% and 41%, respectively) in depressives (n=19)
versus controls (n=19).This observation is consistent with
evidence that the adrenal gland is also abnormally
enlarged in MDD,
1 which would putatively result from
chronically elevated stimulation of the adrenal cortex by
adrenocorticotropic hormone (ACTH).
Postmortem neuropathological assessments
of mood disorders
Most of the regions where MRI studies demonstrated
volumetric abnormalities in mood disorders were also
shown to contain histopathological changes or gray mat-
ter volumetric reductions in postmortem studies of MDD
and BD.Reductions in gray matter volume,thickness,or
wet weight have been reported in the subgenual ACC,
posterolateral orbital cortex, and ventral striatum in
MDD and/or BD subjects relative to controls.
7,9,18,55The
histopathological correlates of these abnormalities
included reductions in glial cells with no equivalent loss
of neurons,reductions in synapses or synaptic proteins,
elevations in neuronal density, and reductions in neu-
ronal size.
9,17,18,20,40,64,65 Abnormal reductions in glial cell
counts and density,and/or glia-to-neuron ratios have also
been found in MDD in Brodmann area (BA) 24 cortex
of the pregenual ACC,
20 the dorsal anterolateral PFC
(BA9),
21,66 and the amygdala.
1,67 Finally,the mean size of
neurons was reduced in the dorsal anterolateral PFC
(BA9) in MDD subjects relative to controls,
18 and the
density of neurons was decreased in the ACC in BD.
68 In
several of these studies, the decreases were largely
accounted for by differences in the left hemisphere.
1,7,9,17,67
In the amygdala and the dorsal anterolateral PFC (BA9),
the glial type that specifically differed between MDD and
control samples was the oligodendrocytes. In contrast,
astrocyte and microglial cell counts did not differ signifi-
cantly between MDD or BD samples and healthy control
samples in the amygdala.
1 Oligodendroglia are best char-
acterized for their role in myelination,and the reduction
in oligodendrocytes may conceivably arise secondary to
an effect on myelin,either through demyelination,abnor-
mal development,or atrophy in the number of myelinated
axons.Notably,the myelin basic protein concentration was
found to be decreased in the frontal polar cortex (BA10)
in MDD subjects.
69 Compatible with these data,the con-
centration of white matter within the vicinity of the amyg-
dala
27 and the white matter volume of the genual and sple-
nial portions of the corpus callosum are abnormally
reduced in MDD and BD.
58,59These regions of the corpus
callosum were also smaller in child and adolescent off-
spring of women with MDD who had not yet experienced
a major depressive episode,in comparison to age-matched
controls,suggesting that the reduction in white matter in
MDD reflects a developmental defect that exists prior to
the onset of depressive episodes.
58All of these observa-
tions support the hypothesis that the glial cell loss in mood
disorders is accounted for by a reduction in myelinating
oligodendrocytes.
Further evidence supporting this hypothesis comes from
several reports that deficits in glia in the cerebral cortex
depend upon laminar analysis,with the greatest effects in
layers III,V, and VI.
18,20,70,71 The intracortical plexuses of
myelinated fibers known as “bands of Baillarger”are gen-
erally concentrated in layers III and V.The size of these
plexuses varies across cortical areas, so if the oligoden-
drocytes related to these plexuses were affected,different
areas would be expected to show greater or lesser deficits.
Layer VI in particular has a relatively large component of
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matter.
Finally,a population of satellite oligodendrocytes exists
next to neuronal cell bodies that have largely unknown
functions,but do not appear to have a role in myelination
under normal conditions.
72An electron microscopic study
of the PFC in BD revealed decreased nuclear size,clump-
ing of chromatin,and other types of damage to satellite
oligodendrocytes,including indications of both apoptotic
and necrotic degeneration.
73 Fewer signs of degeneration
were seen in myelin-related oligodendrocytes in white
matter.Satellite oligodendrocytes may play a role in main-
taining the extracellular environment for the surrounding
neurons,which resembles the functions mediated by astro-
cytes.These oligodendrocytes are immunohistochemically
reactive for glutamine synthetase, suggesting that they
function like astrocytes and take up synaptically released
glutamate for conversion to glutamine and cycling back
into neurons.
74 Many studies of glial function have not dis-
tinguished astrocytes from oligodendrocytes,and the two
glial types may share several functions.
In other brain regions,reductions in astroglia have been
reported by postmortem studies of mood disorders.In the
frontal cortex, Johnston-Wilson et al
75 found that four
forms of the astrocytic product glial fibrillary acidic pro-
tein (GFAP) were decreased in mood-disordered subjects
relative to controls,although it remained unclear whether
this decrement reflected a reduction in the astrocyte den-
sity or in GFAP expression.Using immunohistochemical
staining for GFAP,Webster et al
76 did not find significant
differences in cortical astrocytes between controls, and
MDD or BD cases.Other studies also did not find differ-
ences in GFAP between mood disorder cases and con-
trols.
66
Factors that may conceivably contribute to a loss of oligo-
dendroglia in mood disorders include the elevated gluco-
corticoid secretion and glutamatergic transmission evident
during depression and mania.Glucocorticoids affect glia
as well as neurons,
77 and elevated glucocorticoid levels
decrease the proliferation of oligodendrocyte precursors.
78
Moreover,oligodendrocytes express α-amino-3-hydroxy-
5-methyl-4-isoxazolepropionate (AMPA) and kainate-
type glutamate receptors,and are sensitive to excitotoxic
damage from excess glutamate as well as to oxidative
stress.
1These vulnerabilities putatively contribute to oligo-
dendrocyte degeneration in ischemic brain injury and
demyelinating diseases,
79,80 although no data exist to estab-
lish a similar role in mood disorders.The targeted nature
of the reductions in gray matter volume and glial cells to
specific areas of the limbic-cortical circuits that show
increased glucose metabolism during depressive episodes
is noteworthy given the evidence reviewed below that the
glucose metabolic signal is dominated by glutamatergic
transmission.The hypothesis that glutamate transmission
is elevated in these areas in depression was also supported
by a postmortem study in depressed suicide victims.
81
Elevations of glutamate transmission and cortisol secre-
tion in mood disorders may also contribute to reductions
in gray matter volume and synaptic markers by inducing
dendritic atrophy in some brain structures.In the medial
PFC and parts of the hippocampus and amygdala of adult
rodents, the dendritic arbors undergo atrophy or
debranching in response to specific types of repeated or
chronic stress.
82The effects of stress on dendritic arboriza-
tion depend both upon the type of stress applied and
anatomical location.For example,chronic unpredictable
stress produces dendritic atrophy in the basolateral amyg-
dala,whereas chronic immobilization stress increased den-
dritic branching in pyramidal and stellate neurons within
the basolateral amygdala, but did not affect dendritic
arborization in the central nucleus of the amygdala.
83,84
These dendritic reshaping processes depend upon inter-
actions between N-methyl-D-aspartate (NMDA) gluta-
matergic receptor stimulation and glucocorticoid secretion
associated with repeated stress.
82
The depressives with BD and FPDD who show regional
reductions in gray matter volume also show evidence of
having increased cortisol secretion and glutamate trans-
mission.Specifically,depressives with FPDD or BD are
more likely to show abnormal suppression of cortisol
secretion by dexamethasone and blunted hypoglycemic
response to insulin
8 and to release excessive amounts of
cortisol during stress.
8,85 Subjects with FPDD or familial
BD also show elevations of glucose metabolism, which
largely reflects glutamate transmission,in the medial and
orbital PFC,amygdala,ventral striatum,and cingulate cor-
tex regions that show reductions in gray matter volume
and cellular elements.
Association between structural and 
metabolic abnormalities
The glucose metabolic signal is dominated by changes in
glutamate transmission,and so the findings that gray mat-
ter reductions appear to occur specifically in regions that
show hypermetabolism during depression raise the possi-
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in the neuropathology of mood disorders.At least 85% to
90% of the glucose metabolic measure is accounted for by
glutamate transmission from afferent projections origi-
nating within the same structure or from distal struc-
tures.
4,86-89 In the depressed phase of familial MDD and BD,
regional cerebral metabolism and CBF are abnormally
increased in the amygdala, lateral orbital/ventrolateral
PFC,ACC anterior to the genu of the corpus callosum
(“pregenual”ACC), posterior cingulate cortex, ventral
striatum,medial thalamus,and medial cerebellum.
1 During
effective antidepressant drug or electroconvulsive therapy,
metabolic activity decreases in all of these regions,
1,8 com-
patible with evidence that these treatments result in desen-
sitization of NMDA glutamatergic receptors in the frontal
cortex.
90 In addition to these areas of increased metabolic
activity,areas of reduced CBF and metabolism in depres-
sives relative to controls were found in the ACC ventral to
the genu of the corpus callosum (ie,“subgenual”ACC
7)
and the dorsomedial/ dorsal anterolateral PFC.
19,91,92Yet
even in these regions,metabolic activity increases during
the depressive relapse induced by tryptophan depletion (a
dietary challenge that depletes central 5-HT transmis-
sion),
93 and metabolism is increased in the subgenual ACC
in the unmedicated-depressed phase relative to the
unmedicated-remitted phase.In all of these regions where
glucose metabolism is increased in the depressed phase
relative to the remitted phase,reductions in cortex volume
and/or histopathological changes have been found in 
in vivo MRI studies and/or postmortem studies of MDD
and/or BD.
The hypothesis that the elevations in glucose metabolism
seen in these circuits reflect elevations in glutamatergic
transmission is supported by evidence that the anatomical
projections between affected areas are excitatory in
nature.The abnormally increased CBF and metabolism in
the ventrolateral and orbital PFC,ventral ACC,amygdala,
ventral striatum,and medial thalamus evident in depres-
sion (Figure 2) implicate a limbic-thalamo-cortical circuit
involving the amygdala,the mediodorsal nucleus of the
thalamus and the orbital and medial PFC,and a limbic-
striatal-pallidal-thalamic circuit involving related parts of
the striatum and the ventral pallidum along with the com-
ponents of the other circuit.
95The first of these circuits can
be conceptualized as an excitatory triangular circuit,
whereby the basolateral nucleus of the amygdala and the
orbital and medial prefrontal regions are interconnected
by excitatory (especially glutamatergic) projections with
each other and with the mediodorsal nucleus.
96-100 This
means that increased metabolic activity in these structures
would presumably reflect increased synaptic transmission
through the limbic-thalamo-cortical circuit.The limbic-stri-
atal-pallidal-thalamic circuit constitutes a disinhibitory side
loop between the amygdala or PFC and the mediodorsal
nucleus.The amygdala and the PFC send excitatory pro-
jections to overlapping parts of the ventromedial stria-
tum.
101This part of the striatum sends an inhibitory pro-
jection to the ventral pallidum,
102 which in turn sends
GABAergic (GABA, γ-aminobutyric acid), inhibitory
fibers to the mediodorsal nucleus.
99
Implications for the pathogenesis of 
emotion dysregulation
The circuits described above have also been implicated
in the depressive syndromes arising secondary to lesions
or degenerative illnesses.Lesions involving the PFC (eg,
tumors or infarctions) and the diseases of the basal gan-
glia (eg,Parkinson’s disease or Huntington’s disease) are
associated with higher rates of depression than other sim-
ilarly debilitating conditions and result in dysfunction at
distinct points within these circuits and affect synaptic
transmission in diverse ways.
103 Consistent with this
hypothesis,imaging studies of depressive syndromes aris-
ing secondary to neurological disorders have generally
shown results that differ from those reported for primary
mood disorders.For example,in contrast to the findings
of increased CBF or metabolism in parts of the orbital
cortex in primary depressives, orbital cortex flow is
reportedly decreased or not significantly different in sub-
jects with depressive syndromes arising secondary to
Parkinson’s disease,Huntington’s disease,or basal gan-
glia infarction relative to nondepressed subjects with the
same illnesses.
104-107 Primary and secondary depressive
syndromes may thus involve the same neural network,
although the direction of the physiological abnormalities
within individual structures may differ across conditions.
A common substrate in these cases may be dysfunction
of the PFC-striatal modulation of limbic and visceral
functions, because the idiopathic neuropathological
changes evident in the orbital and medial PFC and ven-
tral striatum in primary mood disorders (see above) and
those found in neurodegenerative conditions all appear
to be capable of inducing depressive syndromes (eg,
Parkinson’s disease, Huntington’s disease, and cere-
brovascular disease).
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pathogenesis of depressive and anxiety symptoms in
mood disorders.Although the reciprocal PFC-amygdalar
projections are excitatory in nature,these connections
ultimately appear to activate inhibitory interneurons,
which, in turn, lead to functional inhibition in the pro-
jected field of the amygdala (for PFC-amygdalar projec-
tions) or the medial PFC and ventrolateral PFC.
96,108-110
The function of the PFC in modulating the amygdala
appears to be impaired in mood disorders,according to
functional MRI data showing that abnormally sustained
amygdala activity in response to aversive words or sad
faces in MDD is associated with blunted activation of
PFC areas.
108,111Thus,the volumetric and/or histopatho-
logical changes evident in the subgenual and pregenual
ACC,lateral orbital cortex,dorsomedial/dorsal antero-
lateral PFC,hippocampal subiculum,amygdala,and ven-
tral striatum may interfere with the modulation of emo-
tional behavior,as discussed below.
Ventral ACC 
The ACC ventral and anterior to the genu of the corpus
callosum (“subgenual” and “pregenual,” respectively;
Figure 2) shows complex relationships between CBF,
metabolism, and illness state, which appear to be
accounted for by a left-lateralized reduction in the corre-
sponding cortex, initially demonstrated by MRI-based
morphometric measures
6,12-16,112 and later by postmortem
neuropathological studies of familial BD and MDD.
9Thus,
computer simulations that correct the PET data acquired
from this region for the partial volume effect of the reduc-
tion in gray matter volume measured in MRI scans of the
same subject conclude the “actual”metabolic activity in
the remaining subgenual PFC tissue is increased in depres-
sives relative to controls,and decreases to normative lev-
els during effective treatment.
113This hypothesis appears
to be compatible with the observations that effective anti-
depressant pharmacotherapy results in a decrease in meta-
Clinical research
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Figure 2. Altered metabolism in the prefrontal cortex (PFC) ventral to the
genu of the corpus callosum (c.c.) (ie, subgenual PFC) in mood
disorders. A. Negative voxel t values where glucose metabolism
is decreased in depressives relative to controls in coronal 
(31 mm anterior to the anterior commissure, or y=31) and sagit-
tal (3 mm left of midline, or x=-3) planes of a statistical para-
metric image comparing depressives relative to controls.
7 This
image localized an abnormality in the subgenual portion of the
anterior cingulate cortex (subgenual ACC
7), which was subse-
quently shown to be accounted for by a corresponding reduc-
tion in cortex volume on the left side (see text). Anterior (or left)
is to the left of the image. B. Mean, normalized, glucose meta-
bolic values for the left subgenual ACC measured using mag-
netic resonance imaging (MRI)–based region-of-interest analy-
sis. Metabolism is decreased in depressed subjects with either
bipolar disorder (BD) or major depressive disorder (MDD) relative
to healthy controls. In contrast, subjects scanned in the manic
phase of BD (“bipolar manic”) have higher metabolism than
either depressed or control subjects in this region. *P<0.025 con-
trols versus depressed; †P<0.01 depressed versus manic;
‡P<0.05 controls versus manic. Although none of these subjects
were involved in the study that generated the images shown in
Figure 3, the mean glucose metabolism in this independent sam-
ple of depressives and controls also confirmed the areas of
abnormally increased activity in the depressives in the amygdala,
lateral orbital cortex, ventrolateral PFC, and medial thalamus (not
shown in A, which only illustrates negative t values corre-
sponding to hypometabolic areas in the depressives). 
Figure 2A reproduced with permission from reference 6: Drevets WC,
Price JL, Simpson JR, et al. Subgenual prefrontal cortex abnormalities in
mood disorders. Nature. 1997;386:824-827. Copyright © 1997, Nature
Publishing Group.
Figure 2B reproduced with permission from reference 94: Drevets WC.
Neuroimaging and neuropathological studies of depression: Implications
for the cognitive emotional manifestations of mood disorders. Curr Opin
Neurobiol. 2001;11:240-249. Copyright © 2001, Elsevier.
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manicbolic activity in this region in MDD,
8,10,114 that during
depressive episodes metabolism shows a positive rela-
tionship with depression severity,
8,115,116 and that flow
increases in this region in healthy,nondepressed humans
during sadness induced via contemplation of sad thoughts
or memories.
114,117,118
The reduction in volume in this region exists early in the
illness in familial MDD
11 and BD.
12The gray matter deficit
may nevertheless worsen or initially become apparent fol-
lowing illness onset based upon preliminary evidence in
twins discordant for MDD that the affected twin has a
smaller volume than their unaffected cotwin.
119 Kimbrell
et al
120 reported that the subgenual ACC metabolism cor-
related inversely with the number of lifetime depressive
episodes,compatible with the possibility that the reduction
in metabolism in this region measured via PET reflects a
partial volume effect of a gray matter reduction that wors-
ens with repeated illness.
In the pregenual ACC, Drevets et al
95 initially found
increased CBF in MDD,and subsequent studies extended
this observation by demonstrating complex relationships
between pregenual ACC activity and subsequent antide-
pressant treatment outcome. Wu et al
121 reported that
depressed subjects whose mood improved during sleep
deprivation showed elevated metabolism in the pregenual
ACC and amygdala in their pretreatment scans.Mayberg
et al
122 reported that,while metabolism in the pregenual
ACC was abnormally increased in depressives who sub-
sequently responded to antidepressant drugs,metabolism
was decreased in depressives who later had poor treat-
ment response. Finally, in a tomographic electroen-
cephalographic (EEG) analysis,Pizzagalli et al
123 reported
that depressives who ultimately showed the best response
to nortriptyline showed hyperactivity (higher theta activ-
ity) in the pregenual ACC at baseline,compared with sub-
jects showing the poorer response.During effective anti-
depressant treatment,most PET studies have shown that
pregenual ACC flow and metabolism decrease in post-
treatment scans relative to pretreatment scans.
1The find-
ing that this region contains histopathological changes in
MDD and BD
20,64,68 suggests the hypothesis that the abnor-
mal reduction in metabolism in treatment-nonresponsive
cases reflects more severe reductions in cortex.
In rodents and nonhuman primates, the regions that
appear homologous to human subgenual and pregenual
ACC,namely the infralimbic,prelimbic,and ventral ACCs,
have extensive reciprocal connections with areas impli-
cated in the expression of behavioral, autonomic, and
endocrine responses to threat,stress,or reward/nonreward,
such as the orbital cortex,lateral hypothalamus,amygdala,
accumbens, subiculum, ventral tegmental area (VTA),
raphe, locus ceruleus, periaqueductal grey (PAG), and
nucleus tractus solitarius.
7,124 Humans with lesions that
include these ventromedial PFC structures show abnor-
mal autonomic responses to emotionally provocative stim-
uli and an inability to experience emotion related to con-
cepts that ordinarily evoke emotion.
125 Electrical
stimulation of the ACC elicits fear, panic, or a sense of
foreboding in humans,and vocalization in experimental
animals.
126 Similarly,rats with experimental lesions of pre-
limbic cortex demonstrate altered autonomic,behavioral,
and neuroendocrine responses to stress and fear-condi-
tioned stimuli.The prelimbic and infralimbic cortices con-
tain abundant concentrations of glucocorticoid receptors,
which,when stimulated by corticosterone (CORT),reduce
stress-related HPA activity.
127 Lesions of these cortices con-
sequently result in exaggerated plasma ACTH and CORT
responses to restraint stress.
127 In rats,bilateral or right-lat-
eralized lesions of the ACC and prelimbic and infralimbic
cortex attenuate sympathetic autonomic responses,stress-
induced CORT secretion,and gastric stress pathology dur-
ing restraint stress or exposure to fear-conditioned stim-
uli.
128-130 In contrast,left-sided lesions of this area increase
sympathetic autonomic arousal and CORT responses to
restraint stress.
130 These data suggest that the right sub-
genual PFC facilitates expression of visceral responses
during emotional processing,while the left subgenual PFC
inhibits or modulates such responses.
130 It is thus notewor-
thy that the gray matter reduction in this region in MDD
and BD was lateralized to the left side,suggesting that it
may contribute to disinhibition of neuroendocrine and
autonomic function in depression.
127,131,132
The ventral ACC also appears to participate in processing
of behavioral incentive and motivated behavior.These
areas send efferent projections to the VTA and substantia
nigra,and receive dense dopaminergic innervation from
VTA.
124 In rats,electrical or glutamatergic stimulation of
medial PFC areas that include prelimbic cortex elicits
burst firing patterns from dopamine (DA) cells in the VTA
and increases DA release in the accumbens.
113These pha-
sic,burst firing patterns of DA neurons appear to encode
information regarding stimuli that predict reward and
deviations between such predictions and actual occurrence
of reward.
133Ventral ACC dysfunction may thus conceiv-
ably contribute to disturbances of motivated behavior and
hedonic perception in mood disorders.
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Metabolism and CBF are abnormally decreased in the
dorsolateral and dorsomedial PFC in MDD.
1 The dor-
somedial PFC region includes the dorsal ACC
92 and an
area rostral to the dorsal ACC involving cortex on the
medial and lateral surface of the superior frontal gyrus
(approximately corresponding to BA9 and BA32).
8,19,91
Postmortem studies of MDD and BD found abnormal
reductions in the size of neurons and/or the density of
glia in this portion of BA9,
18,20,134 which may account for
the reduction in metabolism in this region in MDD,and
for the failure of antidepressant drug treatment to cor-
rect metabolism in these areas.
8,19 Nevertheless,currently
remitted MDD subjects who experience depressive
relapse during tryptophan depletion show increased
metabolic activity within these areas in the depressed
versus the remitted conditions,
93 similar to other struc-
tures where histopathological and gray matter volume
changes exist in MDD.
Flow normally increases in the vicinity of this dorso-
medial/dorsal anterolateral PFC in healthy humans as
they perform tasks that elicit emotional responses or
require emotional evaluations.
1 In healthy humans,CBF
increases in this region during anxious anticipation of an
electrical shock to an extent that correlates inversely with
changes in anxiety ratings and heart rate,suggesting that
this region functions to attenuate emotional expression.
In rats, lesions of the dorsomedial PFC result in exag-
gerated heart rate responses to fear-conditioned stimuli,
and stimulation of these sites attenuate defensive behav-
ior and cardiovascular responses evoked by amygdala
stimulation,
128 although the homologue to these areas in
primates has not been clearly established.In primates,
the BA9 cortex sends efferent projections to the lateral
PAG and the dorsal hypothalamus through which it may
modulate cardiovascular responses associated with emo-
tional behavior.
124 It is thus conceivable that dysfunction
of the dorsomedial/dorsal anterolateral PFC may con-
tribute to impairments in the ability to modulate emo-
tional responses in mood disorders.
Lateral orbital/ventrolateral PFC
In the lateral orbital cortex,ventrolateral PFC,and ante-
rior insula,the resting CBF and metabolism have been
abnormally increased in unmedicated subjects with pri-
mary MDD (Figure 3).
1 The elevated activity in these
areas in MDD appears to be mood-state dependent,
95
and,during treatment with somatic antidepressant ther-
apies,flow and metabolism decreases in these regions.
1
The relationship between depression severity and phys-
iological activity in the lateral orbital cortex/ventrolat-
eral PFC is complex. While CBF and metabolism
increase in these areas in the depressed phase relative to
the remitted phase of MDD,the magnitude of these mea-
sures is inversely correlated with ratings of depressive
ideation and severity.
95,116,135 Moreover,while metabolic
activity is abnormally increased in these areas in treat-
ment-responsive unipolar and bipolar depressives,more
severely ill or treatment-refractory samples show CBF
and metabolic values lower than or not different from
those of controls.
81,139This inverse relationship between
orbital cortex/ventrolateral PFC activity and ratings of
depression severity extends to some other emotional
states as well.Posterior orbital cortex flow also increases
in subjects with obsessive-compulsive disorder or simple
animal phobias during exposure to phobic stimuli and in
healthy subjects during induced sadness,
140-142 with the
change in posterior orbital CBF correlating inversely
with changes in obsessive thinking,anxiety,and sadness,
respectively.
These data appear to be consistent with electrophysio-
logical and lesion analysis data showing that parts of the
orbital cortex participate in modulating behavioral and
visceral responses associated with defensive,emotional,
and reward-directed behavior as reinforcement contin-
gencies change.
124,143,144The orbital cortex and amygdala
send overlapping projections to each of these structures
and to each other through which they appear to modu-
late each other’s neural transmission.
124,143,145
Activation of the orbital cortex during depression may
thus reflect compensatory attempts to attenuate emo-
tional expression or interrupt unreinforced aversive
thought and emotion. Consistent with this hypothesis,
cerebrovascular lesions of the orbital cortex are associ-
ated with an increased risk for depression.
146These obser-
vations also suggest that the reduction of CBF and
metabolism in the orbital cortex and ventrolateral PFC
during antidepressant drug treatment may not be a pri-
mary mechanism through which such agents ameliorate
depressive symptoms.Instead,direct inhibition of patho-
logical limbic activity in areas such as the amygdala and
ventral ACC may attenuate the mediation of depressive
symptoms.
8The orbital cortex neurons may thus “relax,”
as reflected by the return of metabolism to normal lev-
Clinical research
208els,as antidepressant drug therapy attenuates the patho-
logical limbic activity to which these neurons putatively
respond.
145
The amygdala
In the amygdala,neurophysiological activity is altered
both at rest and during exposure to emotionally valenced
stimuli in some depressive subgroups.The basal CBF and
metabolism are elevated in mood-disordered subgroups
who meet criteria for FPDD (Figure 3),
8,95,135,136 for MDD
melancholic subtype,
148 type II or nonpsychotic type I
BD,
136,149 or for those who are responsive to sleep depri-
vation.
121 In contrast,metabolism has not been abnormal
in unipolar depressives meeting criteria for depression
spectrum disease,
136,137 or in MDD samples meeting
Diagnostic and Statistical Manual of Mental Health
Disorders (DSM) criteria,
150-152 although the interpreta-
tion of the latter results was confounded by technical
problems that reduced sensitivity for measuring amyg-
dala activity.
136 During antidepressant treatment that both
attenuates depressive symptoms and prevents relapse,
amygdala metabolism decreases toward normative lev-
els.
8
Functional imaging data acquired as subjects view emo-
tionally valenced stimuli that normally activate the amyg-
dala also demonstrate altered physiological responses in
MDD.In the left amygdala,the hemodynamic response
to viewing fearful faces was blunted in depressed chil-
dren
153 and depressed adults,
94 consistent with the eleva-
tion of basal CBF and metabolism in the left amygdala
in such cases (physiologically activated tissue is expected
to show an attenuation of further rises in the hemody-
namic/metabolic signal in response to tasks that normally
engage the same tissue).The duration of the amygdala
response to emotionally valenced stimuli is also abnor-
mally prolonged in response to sad stimuli in depression.
Drevets et al
94 observed that,although the initial amyg-
dala CBF response to sad faces was similar in depressives
and controls,this response habituated during repeated
Neuroplasticity in mood disorders - Drevets Dialogues in Clinical Neuroscience - Vol 6 . No.2 . 2004
209
Figure 3. Areas of abnormally increased blood flow in subjects with
major depressive disorder (MDD). The image sections shown
are from an image of t values, produced by a voxel-by-voxel
computation of the unpaired t statistic to compare regional
CBF between a depressed sample selected according to crite-
ria for familial pure depressive disease (FPDD) (n=13) and a
healthy control sample (n=33).
95 The positive t values shown
correspond to areas where flow is increased in the depressives
relative to the controls. The abnormal activity in these regions
was replicated using glucose metabolism imaging in indepen-
dent subject samples.
8,135,136 A. Sagittal section at 17 mm left of
midline illustrating areas of increased CBF in depression in the
amygdala and orbital cortex. B. Area of increased flow
extended through the lateral orbital cortex to the ventrolateral
prefrontal cortex (VLPFC) and anterior insula.
8,95 The x coordi-
nate locates sagittal sections in millimeters to the left of mid-
line. The PET images in A and B from which the t image was
generated have been stereotaxically transformed to the coor-
dinate system of Talairach and Tournoux,
137 from which the cor-
responding atlas outline is shown. Anterior is left. 
Figure 3A reproduced with permission from reference 126: Price JL,
Carmichael ST, Drevets WC. Networks related to the orbital and medial
prefrontal cortex: a substrate for emotional behavior? Prog Brain Res.
1996;107:523-536. Copyright © 1996, Elsevier.
Figure 3B reproduced with permission from reference 138: Drevets WC,
Videen TO, Snyder AZ, MacLeod AK, Raichle ME. Regional cerebral
blood flow changes during anticipatory anxiety. Soc Neurosci Abstr.
1994;20:368. Copyright © 1994, Society for Neuroscience.
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x=-41exposure to the same stimuli in the controls,but not in
the depressives over the imaging period.Similarly,Siegle
et al
44 reported that hemodynamic activity increased in
the amygdala during exposure to negatively valenced
words to a similar extent in depressives and controls,but,
while the hemodynamic response rapidly fell to baseline
in the controls,it remained elevated in the depressives.
The amygdala plays major roles in organizing other
behavioral,neuroendocrine,and autonomic aspects of
emotional and stress responses to experiential stimuli.
For example,the amygdala facilitates stress-related cor-
ticotropin-releasing hormone (CRH) release
154 and elec-
trical stimulation of the amygdala in humans increases
cortisol secretion,
155 suggesting a mechanism via which
excessive amygdala activity may participate in inducing
the CRH and cortisol hypersecretion that is evident in
MDD.In PET studies of MDD and BD,CBF and metab-
olism in the left amygdala correlates positively with
stressed plasma cortisol secretion,which may reflect the
effect of either amygdala activity on CRH secretion or
cortisol or CRH on amygdala function.
136
If the reduction in amygdala volume is associated with
reductions in synaptic contacts formed by afferent projec-
tions from regions known to modulate amygdala function,
then amygdala neuronal activity may become disinhibited.
The above reports that amygdala blood flow and metabo-
lism are abnormally elevated and hemodynamic responses
to emotional stimuli are abnormally persistent in MDD
support this hypothesis.Notably,Siegle et al
44 reported that
the abnormally prolonged hemodynamic responses of the
amygdala to sad words occurred particularly in the MDD
subjects who had reduced amygdala volumes.If the neu-
rotrophic effects of mood-stabilizing drugs restore and
protect modulatory connections formed between the
amygdala and cortex,
1 then the volumetric changes
observed during treatment may contribute to their ther-
apeutic effects in mood disorders.
Abnormalities in anatomically related limbic and 
subcortical structures
In the medial thalamus and ventral striatum,CBF and
metabolism are abnormally elevated in the depressed
phase of MDD and BD, and decrease during antide-
pressant pharmacotherapy.
8,95,134,136,154,156,157 Several groups
also reported abnormally increased CBF in the posterior
cingulate cortex in the unmedicated,depressed phase of
MDD.
8,112,158 Bench et al
158 specifically reported that the
elevation of posterior cingulate flow in depressives rela-
tive to controls correlated positively with anxiety ratings.
Exposure to aversive stimuli of various types results in
increased physiological activity in the posterior cingulate
cortex.
159 The posterior cingulate cortex sends major
anatomical projections to the pregenual ACC.
160
Neuroreceptor imaging abnormalities
in mood disorders
Neuroreceptor imaging studies of mood disorders have
demonstrated reductions in 5-HT1A receptor binding in
mood disorders,which would appear to hold major impli-
cations for alterations in neuroplasticity in these condi-
tions.Both presynaptic (in the raphe) and postsynaptic
(insula,anterior,and posterior cingulate cortices,parieto-
occipital cortex,orbital/ventrolateral PFC) 5-HT1A bind-
ing is abnormally decreased in MDD and panic disorder
(irrespective of the current presence of comorbid depres-
sion),and postsynaptic 5-HT1A receptor binding is also
decreased in BD.
85,116,161-165The magnitudes of these differ-
ences have been similar to those found by postmortem
studies of primary mood-disordered samples
17,165 and
depressed suicide victims.
166These data are also compat-
ible with results of studies showing that MDD and panic
disorder subjects show blunted thermic and adrenocor-
ticotropin/cortisol responses to 5-HT1A receptor agonist
challenge.
85,162
The 5-HT1A receptor plays major roles in the neuroplas-
ticity involving serotonergic and other neurons.
167,168 In
addition,during fetal development and subsequently dur-
ing 5-HT neuronal injury, stimulation of astrocyte and
radial glial cell-based 5-HT1A receptors results in release
of the trophic factor S100β,which promotes 5-HT neu-
ronal arborization.
168,169 If glial function is reduced during
5-HT system development in BD and MDD, it is con-
ceivable that arborization of the 5-HT neurons may be
attenuated, potentially reflected by the widespread
reductions of 5-HT transporter and postsynaptic 5-HT1A
receptor expression seen in MDD.
17,85,116,163,166,170 Such a
hypoplastic process may also underlie the finding that the
area expressing 5-HT1A receptors in the dorsal raphe
nucleus is abnormally decreased in depressed suicides.
166
It is conceivable that the persistently increased anxiety
behaviors and the exaggerated fear and behavioral
despair responses shown by 5-HT1A receptor knockout
mice at least partly reflect effects of deficient 5-HT1A
receptor function on neuroplasticity during neurodevel-
Clinical research
210opment.
162 It remains unclear, however, whether the
reduction in 5-HT1A receptor function and expression
constitutes a neurodevelopmental or an acquired abnor-
mality in mood disorders.
165
Concluding remarks
The convergent results from studies of mood disorders
conducted using neuroimaging,lesion analysis,and post-
mortem techniques support models in which the signs
and symptoms of major depression can emanate from
dysfunction within PFC,striatal,and brain stem systems
that modulate emotional behavior.Antidepressant ther-
apies may compensate for this dysfunction by attenuat-
ing the pathological limbic activity that mediates such
symptoms,
9 and by increasing genetic transmission of
neurotrophic factors that exert neuroplastic effects within
the pathways modulating emotional expression.
14 ❏
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Neuroplasticidad en los trastornos afectivos
Los estudios neuropatológicos y de neuroimágenes en la depresión mayor (DM) y en el trastorno bipolar (TB)
han identificado anormalidades de la estructura cerebral en áreas de la corteza prefrontal, la amígdala, el
cuerpo estriado, el hipocampo, el giro parahipocámpico y el núcleo del rafe. Estas anormalidades estructu-
rales en las neuroimágenes se mantienen más allá de los episodios de la enfermedad y las evidencias preli-
minares sugieren que en algunos casos ellas pueden aparecer antes del inicio de los episodios depresivos en
sujetos con alto riesgo familiar de DM. En otros casos, la magnitud de la anormalidad se correlaciona con el
tiempo que lleva la depresión. Estudios histopatológicos postmortem de estas regiones han mostrado dis-
minuciones anormales de  marcadores sinápticos y de células gliales y, en raros casos, disminución de  neuro-
nas en la DM y el TB. Muchas de las regiones afectadas por estas alteraciones estructurales muestran un
aumento del metabolismo de la glucosa durante los episodios depresivos. Dado que la señal metabólica de
glucosa está comandada por la transmisión glutamatérgica, estos datos sustentan el argumento a favor del
incremento de la transmisión del aminoácido excitatorio en los circuitos límbico-córtico-estriato-pálido-talá-
micos durante la depresión. Algunos de los sujetos de las muestras en que se encontraron estas anormalida-
des metabólicas también tuvieron cifras elevadas de cortisol plasmático en respuesta al estrés. La aparición
concomitante del aumento de la transmisión glutamatérgica y de la hipersecreción de cortisol incrementa la
probabilidad que las disminuciones del volumen de sustancia gris en los sujetos con depresión se deba en
parte a los procesos equivalentes a los de la atrofia dendrítica inducida por el estrés crónico en roedores adul-
tos, lo que depende de las interacciones entre el aumento de la secreción de glucocorticoides y la estimula-
ción del receptor de glutamato N-metil-D-aspártico (NMDA). Algunos antidepresivos y estabilizadores del
ánimo que ejercen efectos neurotróficos en roedores parece que revierten o disminuyen las anormalidades
del volumen de sustancia gris en humanos con trastornos afectivos. Estos efectos neurotróficos pueden estar
relacionados íntegramente con los efectos terapéuticos de dichos fármacos, ya que se sabe que las regiones
afectadas por alteraciones estructurales en los trastornos afectivos tienen un papel importante en la modu-
lación de las respuestas endocrina, autonómica, conductual y emocional que se experimenta frente al estrés.55. Baumann B, Danos P, Krell D, et al. Reduced volume of limbic system-
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Neuroplasticité dans les troubles de l’humeur
Les études de neuropathologie et de neuro-imagerie des troubles dépressifs majeurs (TDM) et des troubles bipolaires (TB)
ont identifié des anomalies de la structure cérébrale dans les aires du cortex préfrontal, de l’amygdale, du striatum, de
l’hippocampe, du gyrus parahippocampique et du noyau du raphé. Ces anomalies structurelles à l’image persistent à tra-
vers les épisodes de la maladie et des arguments antérieurs suggèrent qu’elles peuvent se produire avant l’apparition des
épisodes dépressifs chez les sujets à haut risque familial de TDM. Dans d’autres cas, l’importance des anomalies serait liée
à la durée de la dépression. Des études histopathologiques post mortem de ces régions ont montré des réductions anor-
males des marqueurs synaptiques et des cellules gliales et, dans quelques rares cas, des diminutions du nombre des neu-
rones dans les TDM et les TB. De nombreuses régions atteintes par ces anomalies structurelles présentent un métabolisme
du glucose augmenté pendant ces épisodes dépressifs. La transmission glutamatergique dominant le signal métabolique
du glucose, ces données confortent un autre argument à savoir que la transmission de l’acide aminé excitateur est élevée
dans les circuits limbiques-corticaux-striataux-pallidaux-thalamiques pendant la dépression. Certains échantillons, chez
des sujets chez qui on a trouvé des anomalies métaboliques, ont également montré des concentrations anormalement
élevées de cortisol plasmatique en réponse au stress. L’apparition concomitante de l’augmentation de la transmission glu-
tamatergique et de l’hypersécrétion de cortisol accroît la possibilité que les réductions de volume de la substance grise
chez ces personnes dépressives soient en partie justifiées par des processus identiques à ceux de l’atrophie dendritique
induite par le stress chronique chez les rongeurs adultes, qui dépend des interactions entre la sécrétion élevée des glu-
cocorticoïdes et la stimulation du récepteur glutamatergique N-méthyl-D-aspartate (NMDA). Certains médicaments anti-
dépresseurs et thymorégulateurs exerçant des effets neurotrophiques chez les rongeurs semblent inverser ou atténuer
les anomalies du volume de la substance grise chez les humains atteints de troubles de l’humeur. Ces effets neu-
rotrophiques peuvent être intégralement liés aux effets thérapeutiques de tels médicaments, parce qu’il est reconnu que
les régions affectées par des anomalies structurelles au cours des troubles de l’humeur jouent un rôle majeur dans la mo-
dulation des réponses aux agents stressants au niveau de l’expérience endocrine, autonome, comportementale et émo-
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